Results 21 to 30 of about 657,649 (153)

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance

, 2022
Tropomyosin receptor kinase (TRK) secondary mutations mediating acquired resistance, especially at the solvent-front (SF) and the DFG motif, represent an unmet clinical need.
Yongjin Wang (371447), Zhi-Min Zhang (848852), Zhang Zhang (14172), Zuqin Wang (12422128), Yang Zhou (65942), Shuang Xiang (11253045), Xiaojuan Song (6273563), Zhengchao Tu (542105), Jie Wang (16762), Ke Ding (309244), Xiaoyun Lu (1390002)   +10 more
core   +3 more sources

Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China

Thoracic Cancer, 2022
Gene fusions can drive tumor development for multiple types of cancer. Currently, many drugs targeting gene fusions are being approved for clinical application.
Chunwei Xu, Lu Si, Wenxian Wang, Ziming Li, Zhengbo Song, Qian Wang, Aijun Liu, Jinpu Yu, Wenfeng Fang, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Lei Lei, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Xiao Hu, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Jiancheng Luo, Hongtao Jia, Xiaowei Dong, Fei Pang, Kai Wang, Liping Wang, Youcai Zhu, Yanru Xie, Xinqin Lin, Jing Cai, Jia Wei, Fen Lan, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Bing Wan, Donglai Lv, Qing Wei, Jin Kang, Jiatao Zhang, Chao Zhang, Genhua Yu, Juanjuan Ou, Lin Shi, Zhongwu Li, Zhefeng Liu, Jing Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Liu Yang, Guansong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Shenglin Ma, Biyun Wang, Xiaotian Zhang, Yong Song, Yuanzhi Lu   +110 more
doaj   +1 more source

NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects

Diagnostics, 2021
Tropomyosin receptor kinase (TK) is encoded by the neurotrophic tyrosine receptor kinase genes (NTRK) 1, 2, and 3, whose activation plays an important role in cell cycle proliferation and survival.
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, Elly Marcq, Patrick Pauwels   +4 more
doaj   +1 more source

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Case Reports in Oncology, 2023
In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Lorenz Frehner, Simon Haefliger, Ferdinando Cerciello, Tobias Grob, Sabine Schmid   +4 more
doaj   +1 more source

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. [PDF]

, 2022
Larotrectinib and entrectinib are tumor-agnostic tropomyosin receptor kinase (TRK) inhibitors that are indicated for the treatment of advanced or metastatic solid tumor cancers with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
Carlson, Josh J, Sullivan, Sean D, Italiano, Antoine, Lassen, Ulrik, Brose, Marcia S, Federman, Noah, Kummar, Shivaani   +6 more
core   +3 more sources

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

, 2021
On-target resistance to next-generation TRK inhibitors in TRK fusion-positive cancers is largely uncharacterized. In patients with these tumors, we found that TRK xDFG mutations confer resistance to type I next-generation TRK inhibitors designed to ...
Toska, Eneda, Scaltriti, Maurizio, Rix, Uwe, Jagadeeshan, Sankar, Schram, Alison M., Vasan, Neil, Baldino, Laura, Kulick, Amanda, Kannan, Srinivasaraghavan, Novoplansky, Ofra, Gorelick, Alexander N., Wu, Fan, Verma, Chandra S., Berger, Michael F., de Stanchina, Elisa, Drilon, Alexander, Hyman, David M., Kannan, Ram, Misale, Sandra, Shifman, Sophie, Arruabarrena-Aristorena, Amaia, Lee, Ji Eun, Kittane, Srushti, Bardelli, Alberto, Liao, Yi, Ventura, Andrea, Won, Helen H., Taylor, Barry S., Hechtman, Jaclyn F., Cocco, Emiliano, Mussolin, Benedetta, Elkabets, Moshe, Cai, Yanyan, Arena, Sabrina   +33 more
core   +1 more source

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

Current Oncology, 2021
The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao   +17 more
doaj   +1 more source

Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma

Frontiers in Oncology, 2023
NTRK fusions are validated oncogenic drivers of various adult and pediatric tumor types, including thyroid cancer, and serve as a therapeutic target. Recently, tropomyosin receptor kinase (TRK) inhibitors, such as entrectinib and larotrectinib, display ...
Qing-Xiang Yu, Wen-Jun Zhao, He-Yue Wang, Lei Zhang, Lan Qin, Lei Zhang, Jian-li Han   +6 more
doaj   +1 more source

NTRK fusion in Japanese colorectal adenocarcinomas

Scientific Reports, 2021
NTRK fusion-positive tumors are known to be highly sensitive to TRK inhibitors, such as larotrectinib and entrectinib. Therefore, identification of patients who can potentially benefit from these inhibitors is important; however, the frequency of NTRK ...
Yuya Yamashiro, Taisei Kurihara, Takuo Hayashi, Yoshiyuki Suehara, Takashi Yao, Shunsuke Kato, Tsuyoshi Saito   +6 more
doaj   +1 more source

gene amplification in patients with metastatic cancer [PDF]

Precision and Future Medicine, 2017
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of cancers, and tyrosine kinase inhibitors targeting the tropomyosin receptor kinase (TRK) receptor are currently in clinical trials. However, no reports are
Su Jin Lee, Nayoung K. D. Kim, Se-Hoon Lee, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Woong Yang Park, Hee Jin Bang, Kyoung-Mee Kim, Keunchil Park, Jeeyun Lee   +13 more
doaj   +1 more source